Sibopirdine
![]() | |
Clinical data | |
---|---|
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
139781-09-2 ![]() |
PubChem (CID) | 9929210 |
ChemSpider |
169416 ![]() |
UNII |
7IKM67CSEQ ![]() |
KEGG |
D05833 ![]() |
Chemical and physical data | |
Formula | C23H18N4 |
Molar mass | 350.415 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
![]() ![]() |
Sibopirdine, also known as EXP921, is a nootropic drug.[1]
Synthesis

Sibopirdine synthesis: DuPont Merck Pharmaceutical Company; U.S. Patent 5,272,269 (1993).
4,5-Diazafluoren-9-one was the starting material.
See also
References
- ↑ Wong, YN; Quon, CY; Holm, KA; Burcham, DL; Frey, NL; Huang, SM; Lam, GN (February 1996). "Pharmacokinetics and metabolism of EXP921, a novel cognitive enhancer, in rats.". Drug metabolism and disposition: the biological fate of chemicals. 24 (2): 172–9. PMID 8742228.
This article is issued from Wikipedia - version of the 7/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.